Dei-Adomakoh Yvonne A, Akpalu Josephine, Yawson Alfred E, Ekem Ivy, Reynolds Margaret, Atiase Yacoba
University of Ghana Medical School, Department of Haematology, Accra, Ghana.
Korle Bu teaching hospital, Department of Medicine, Accra, Ghana.
Ghana Med J. 2019 Jun;53(2):156-162. doi: 10.4314/gmj.v53i2.11.
Glucocorticoids (steroids) play a key role in the management of multiple medical conditions including haematological disorders. This study looked at the prevalence of steroid induced dysglycaemia in patients with haematological disorders receiving steroids as part of their treatment with the view of modifying its use and selection of patients where necessary.
A retrospective review of haematology patients on treatment regimens including steroids. Information extracted included, demographic characteristics, clinical information such as age, gender, haematological disorder, type of steroid, daily and cumulative dose of steroid, duration of therapy, family history of diabetes and alcohol use.
The case records of 351 haematology patients were reviewed. However, eight patients with dysglycaemia before therapy were excluded. The median age of patients was 51.0 ± 26.0(IQR: Interquartile Range) years, with an age range of 13 to 87 years, and a female: male ratio of 1.2: 1 (p= 0.778). The prevalence of Steroid-Induced Dysglycaemia (SID) was 3.79% with a mean diagnosis interval of 8.8 + 2.1 months. Overall, 245 (71.4%) patients were on continuous steroids. Among the 13 patients who developed SID, 11 (84.6%) were on continuous steroids. In the majority of the patients (97.1%) there was no family history of diabetes in a first degree relative. Significant differences were found between patients with normoglycaemia and those with dysglycaemia with respect to age (p=0.049) and duration of steroid therapy (p=0.024).
The prevalence of steroid-induced dysglycaemia is relatively low among Ghanaian patients with haematological disorders on steroid based chemotherapy.
None declared.
糖皮质激素（类固醇）在包括血液系统疾病在内的多种医疗状况的管理中发挥着关键作用。本研究旨在探讨接受类固醇治疗的血液系统疾病患者中类固醇诱导性血糖异常的患病率，以便在必要时调整其使用方法并选择合适的患者。
对接受包括类固醇在内治疗方案的血液学患者进行回顾性研究。提取的信息包括人口统计学特征、临床信息，如年龄、性别、血液系统疾病、类固醇类型、类固醇的每日剂量和累积剂量、治疗持续时间、糖尿病家族史和饮酒情况。
对351例血液学患者的病历进行了回顾。然而，排除了8例治疗前血糖异常的患者。患者的中位年龄为51.0±26.0（四分位间距：IQR）岁，年龄范围为13至87岁，女性与男性比例为1.2:1（p = 0.778）。类固醇诱导性血糖异常（SID）的患病率为3.79%，平均诊断间隔为8.8±2.1个月。总体而言，245例（71.4%）患者接受持续类固醇治疗。在发生SID的13例患者中，11例（84.6%）接受持续类固醇治疗。大多数患者（97.1%）一级亲属中无糖尿病家族史。血糖正常患者与血糖异常患者在年龄（p = 0.049）和类固醇治疗持续时间（p = 0.024）方面存在显著差异。
在接受基于类固醇化疗的加纳血液系统疾病患者中，类固醇诱导性血糖异常的患病率相对较低。
未声明。
